New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 4, 2013
07:57 EDTVRXValeant sees FY13 impact from generics >$100M in revenues
Sees $40M-$50M in revenue declines as a result of planned divestitures. Sees Efinaconazole launch breakeven in 2013. Sees FY13 Solodyn revenue $250M-$275M.
News For VRX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
April 9, 2015
11:39 EDTVRXPershing Square, Valeant, Allergan drop lawsuit over buyout
Subscribe for More Information
April 8, 2015
12:17 EDTVRXOn The Fly: Midday Wrap
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use